Compare S&P Global Inc (SPGI) vs 22nd Century Group Inc (XXII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
S&P Global Inc vs 22nd Century Group Inc — how do they compare? S&P Global Inc trades at $406.16 (market cap $118.72B), while 22nd Century Group Inc trades at $0.84 (market cap $621.67K). The key difference: S&P Global Inc is far larger — about 190969.5× 22nd Century Group Inc's market cap, and S&P Global Inc pays a 0.96% dividend while 22nd Century Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold S&P Global Inc for 123 Days and 22nd Century Group Inc for 32 Days on average.
| SPGI | XXII | |
|---|---|---|
Market Cap | $118.72B | $621.67K |
Volume | 1,647,917 | 45,625 |
Sector | Financials | Consumer Staples |
52-Week High | $517.92 | $483.00 |
52-Week Low | $370.42 | $0.80 |
Typical Hold Time | 123 Days | 32 Days |
Enterprise Value | $130.21B | -$3.69M |
Dividend Yield | 0.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
S&P Global (SPGI) trades at $395.18, down 0.24% on the day, with a bearish technical signal despite strong fundamentals. The company reported robust financials with $15.34B revenue and 30.54% net income margin for 2025, while recent earnings show mixed quarterly performance. Analyst consensus remains strongly bullish with an $509.50 price target, supported by 24 buy ratings. Recent developments include expansion into digital asset risk assessment and AI-driven growth initiatives.
The stock presents a compelling long-term investment opportunity given its strong profitability, market leadership, and analyst support, though technical indicators suggest near-term caution. Key risks include market volatility and execution of growth initiatives, while the 29% upside to consensus target offers significant potential reward for patient investors.
22nd Century Group (XXII) trades at $0.89, down 0.94% today, with a bearish technical signal despite oversold RSI readings. The company shows severe financial stress with negative gross margins of -54.6% and net income margin of -76.01%, though valuation metrics appear low with P/S of 0.09 and P/B of 0.03. Recent news highlights regulatory progress in nicotine reduction initiatives and expanded retail distribution for VLN products.
While analyst consensus remains bullish with 75% buy ratings and a $1,240 price target, fundamental challenges persist with consecutive earnings misses and negative cash flow from operations. The stock presents high-risk speculation on regulatory adoption of reduced-nicotine standards, requiring careful risk assessment given the company's ongoing losses and cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About S&P Global Inc
S&P Global provides data and benchmarks to capital and commodity market participants. In 2021 and excluding IHS Markit, S&P Ratings was over 45% of the firm's revenue and over 55% of the firm's operating income. S&P Ratings is the largest credit rating agency in the world. The firm's other segments include Market Intelligence, Indices, and Platts. Market Intelligence provides desktop tools and other data solutions to investment banks, corporations, and other entities. Indices provides benchmarks for financial markets and is monetized through subscriptions, asset-based fees, and transaction-based royalties. Platts provides benchmarks to commodity markets, principally petroleum.
Read more on SPGI →About 22nd Century Group Inc
22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →
